Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a scoring system to screen for BRCA1/2 mutations.

Methods in molecular biology (Clifton, N.J.) - 1 Jan 2010

Evans Gareth R, Lalloo Fiona

Abstract excerpt

Selection for genetic testing for pathogenic mutations in BRCA1 and BRCA2 is an important area of healthcare. While testing costs for mutational analysis are falling, costs of tests in North America remain in excess of $3,000. Most countries state that there should be at least a 10-20% likelihood of detecting a mutation in BRCA1 or BRCA2 within a family before mutational analysis is performed. A number of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Carcinoma
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Models, Statistical

Share to North America

Share to Probability

Share to Research Design

Source

Identifiers

PMID: 20721747
DOI: 10.1007/978-1-60761-759-4_14

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a scoring system to screen for BRCA1/2 mutations.PMID 20721747Read ↗

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.Semantic proximity Read ↗

Pathology update to the Manchester Scoring System based on testing in over 4000 families.Semantic proximity Read ↗

The Manchester Scoring System for predicting BRCA1/2 mutations underperforms in Arabic Omani breast cancer patients.Semantic proximity Read ↗

Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for <i>BRCA1</i> and <i>BRCA2</i> testingSemantic proximity Read ↗

Selecting a BRCA risk assessment model for use in a familial cancer clinic.Semantic proximity Read ↗

Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.Semantic proximity Read ↗

Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.Semantic proximity Read ↗

Is multiple SNP testing in BRCA2 and BRCA1 female carriers ready for use in clinical practice? Results from a large Genetic Centre in the UK.Semantic proximity Read ↗

A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening.Semantic proximity Read ↗

Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier.Semantic proximity Read ↗

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.Semantic proximity Read ↗

Evaluation of two different models to predict BRCA1 and BRCA2 mutations in a cohort of Danish hereditary breast and/or ovarian cancer families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.